3 Stocks Moving The Health Care Sector Upward

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 74 points (-0.4%) at 17,027 as of Monday, July 21, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 889 issues advancing vs. 2,085 declining with 146 unchanged.

The Health Care sector currently sits down 0.5% versus the S&P 500, which is down 0.4%. A company within the sector that increased today was Alexion Pharmaceuticals ( ALXN), up 0.5%. On the negative front, top decliners within the sector include DaVita HealthCare Partners ( DVA), down 3.4%, Perrigo ( PRGO), down 1.7%, Zimmer Holdings ( ZMH), down 1.3%, Stryker Corporation ( SYK), down 1.0% and Fresenius Medical Care AG & Co. KGaA ( FMS), down 1.0%.

TheStreet would like to highlight 3 stocks pushing the sector higher today:

3. Jazz Pharmaceuticals ( JAZZ) is one of the companies pushing the Health Care sector higher today. As of noon trading, Jazz Pharmaceuticals is up $2.43 (1.7%) to $144.72 on light volume. Thus far, 291,231 shares of Jazz Pharmaceuticals exchanged hands as compared to its average daily volume of 824,700 shares. The stock has ranged in price between $140.00-$144.82 after having opened the day at $142.07 as compared to the previous trading day's close of $142.29.

Jazz Pharmaceuticals Public Limited Company, a specialty biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. Jazz Pharmaceuticals has a market cap of $8.6 billion and is part of the drugs industry. Shares are up 11.9% year-to-date as of the close of trading on Friday. Currently there are 9 analysts who rate Jazz Pharmaceuticals a buy, no analysts rate it a sell, and 1 rates it a hold.

TheStreet Ratings rates Jazz Pharmaceuticals as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, good cash flow from operations and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, disappointing return on equity and feeble growth in the company's earnings per share. Get the full Jazz Pharmaceuticals Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

2. As of noon trading, Valeant Pharmaceuticals International ( VRX) is up $3.25 (2.7%) to $125.22 on average volume. Thus far, 1.8 million shares of Valeant Pharmaceuticals International exchanged hands as compared to its average daily volume of 3.5 million shares. The stock has ranged in price between $121.47-$125.23 after having opened the day at $122.16 as compared to the previous trading day's close of $121.97.

Valeant Pharmaceuticals International, Inc. develops, manufactures, and markets pharmaceuticals, over-the-counter (OTC) products, and medical devices in the areas of eye health, dermatology, and neurology therapeutic classes worldwide. Valeant Pharmaceuticals International has a market cap of $40.8 billion and is part of the drugs industry. Shares are up 3.9% year-to-date as of the close of trading on Friday. Currently there are 9 analysts who rate Valeant Pharmaceuticals International a buy, no analysts rate it a sell, and 1 rates it a hold.

TheStreet Ratings rates Valeant Pharmaceuticals International as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance and increase in net income. However, as a counter to these strengths, we also find weaknesses including generally higher debt management risk and disappointing return on equity. Get the full Valeant Pharmaceuticals International Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

1. As of noon trading, Allergan ( AGN) is up $3.42 (2.0%) to $170.82 on average volume. Thus far, 1.6 million shares of Allergan exchanged hands as compared to its average daily volume of 4.1 million shares. The stock has ranged in price between $166.34-$171.25 after having opened the day at $168.04 as compared to the previous trading day's close of $167.40.

Allergan, Inc. operates as a multi-specialty health care company primarily in the United States, Europe, Latin America, and the Asia Pacific. Allergan has a market cap of $49.2 billion and is part of the drugs industry. Shares are up 49.3% year-to-date as of the close of trading on Friday. Currently there are 5 analysts who rate Allergan a buy, 1 analyst rates it a sell, and 7 rate it a hold.

TheStreet Ratings rates Allergan as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, compelling growth in net income, good cash flow from operations and solid stock price performance. We feel these strengths outweigh the fact that the company is trading at a premium valuation based on our review of its current price compared to such things as earnings and book value. Get the full Allergan Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

null

More from Markets

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

Jim Cramer: The 10-Year Yield Could Go to 2.75%

Jim Cramer: The 10-Year Yield Could Go to 2.75%

Oil Slumps, Gas Spikes Ahead of Holiday Weekend; Assessing the Chipmakers--ICYMI

Oil Slumps, Gas Spikes Ahead of Holiday Weekend; Assessing the Chipmakers--ICYMI

Week Ahead: Wall Street Looks to Jobs Report as North Korea Meeting Less Certain

Week Ahead: Wall Street Looks to Jobs Report as North Korea Meeting Less Certain

Dow and S&P 500 Decline, Energy Shares Fall as U.S. Crude Oil Slides 4%

Dow and S&P 500 Decline, Energy Shares Fall as U.S. Crude Oil Slides 4%